This information is intended for healthcare professionals based in Ireland. If you are not a healthcare professional in Ireland, click here
HOME / ELIQUIS® (APIXABAN) DOSING INFORMATION ELIQUIS IRELAND / RENAL OR HEPATIC IMPAIRMENT
Dosing considerations for Eliquis® (apixaban) in adult patients with renal or hepatic impairment
Dosing considerations in patients with impaired renal function
In the absence of additional dose reduction criteria, ELIQUIS does not require a dose adjustment in patients with mild-to-moderate renal impairment.1
Dosing considerations in adult patients with hepatic impairment across all indications1
Prior to initiating ELIQUIS, liver function testing should be performed.1
EHRA recommends that patients with NVAF undergoing treatment with DOACs have blood samples taken yearly to assess haemoglobin, renal function and liver function2
If patients are ≥75 years old or frail,† samples should be taken every 6 months.2 For patients with renal function CrCl ≤60 ml/min, samples should be taken x-monthly, where x = CrCl/10. Renal function should be checked when necessary. Some patients, for example, those with intercurrent conditions that may affect hepatic or renal function, may require more frequent assessments of renal function.2
ELIQUIS is not recommended in patients with CrCl <15 ml/min, or in patients undergoing dialysis.1
ELIQUIS (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of VTE in adult patients who have undergone elective hip or knee replacement surgery.1
Footnotes:
† Frailty is defined as three or more criteria of unintentional weight loss, self-reported exhaustion, weakness assessed by handgrip test, slow walking speed/gait apraxia or low physical activity.3
ALT = Alanine Aminotransferase AST = Aspartate Aminotransferase BD = Twice Daily CrCl = Creatinine Clearance DOAC = Direct-Acting Oral Anticoagulant DVT = Deep Vein Thrombosis eGFR = Estimated Glomerular Filtration Rate NVAF = Non-Valvular Atrial Fibrillation PE = Pulmonary Embolism ULN = Upper Limit of Normal
References:
- ELIQUIS® (apixaban) Summary of Product Characteristics.
- Steffel J, Collins R et al. European Society of Cardiology. 2021
- Heidbuchel H et al. Europace 2015; 17: 1467–1507
Date of Preparation: September 2025 | Job Description: 432-IE-2500027